文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危前列腺癌联合EBRT与近距离放疗时ADT未见明显生存获益

Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-09-09

该研究基于美国国家癌症数据库46,325例高危前列腺癌患者,分析ADT与外照射放疗(EBRT)联合或不联合近距离放疗的总生存关联。结果显示ADT仅与单纯EBRT组总生存改善相关(aHR 0.91,P=.001),而与联合模式放疗组无显著关联(aHR 1.05,P=.496),交互作用显著(Pinteraction=.036)。

要点

  • 高危前列腺癌单纯EBRT时ADT与总生存改善相关(aHR 0.91,P=.001)。
  • EBRT联合近距离放疗时ADT与总生存无显著关联(aHR 1.05,P=.496)。
  • 两种放疗模式与ADT的交互作用显著(Pinteraction=.036)。

核心结论

  • 与ADT联合EBRT已知的生存获益不同,本研究提示接受EBRT联合近距离放疗的高危前列腺癌患者中ADT可能不改善生存。

研究设计与样本

  • 回顾性队列研究,纳入美国国家癌症数据库2004至2011年46,325例高危前列腺癌男性患者。
  • 高危定义为Gleason评分8-10、临床分期T3-T4或前列腺特异性抗原>20 ng/mL。
  • 采用多因素Cox回归校正社会人口学与临床病理因素,分析ADT与总生存的关联。

主要发现

  • 单纯EBRT组中位随访48.6个月,联合模式放疗组中位随访59.2个月。
  • 85.0%(39,361例)患者接受单纯EBRT,该组ADT与总生存改善相关(aHR 0.91,P=.001)。
  • 联合模式放疗组中ADT与总生存无显著关联(aHR 1.05,P=.496)。
  • 放疗模式与ADT之间存在显著交互作用(Pinteraction=.036)。

临床怎么用

  • 对接受EBRT联合近距离放疗的高危前列腺癌患者,处方ADT前应权衡其长期不良反应与潜在生存获益。
  • 研究结果提示需以非劣效设计开展随机对照试验,评估联合EBRT与近距离放疗时省略ADT的可行性。

局限性

  • 原文未报告本研究的具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although level 1 evidence has demonstrated a survival benefit from the addition of androgen deprivation therapy (ADT) to external beam radiation therapy (EBRT) for patients with high-risk prostate cancer, the benefits of ADT with combined EBRT and brachytherapy for high-risk patients are unclear. We examined the association between ADT and overall survival in a national cohort of high-risk patients treated with EBRT with or without brachytherapy. METHODS AND MATERIALS: We identified 46,325 men in the National Cancer Database with a diagnosis of high-risk prostate cancer (Gleason score 8-10, clinical stage T3-T4, or prostate-specific antigen >20 ng/mL) who were treated with EBRT with or without brachytherapy and ADT from 2004 through 2011. Multivariable Cox regression analysis adjusting for sociodemographic and clinicopathologic factors was used to identify the association between ADT and overall survival. RESULTS: The median follow-up period was 48.6 and 59.2 months for patients treated with EBRT only and combined modality RT, respectively. ADT was associated with an improvement in overall survival for the 85.0% (39,361) of the study cohort who underwent EBRT alone (adjusted hazard ratio 0.91, P=.001) but not for patients treated with combined modality RT (adjusted hazard ratio 1.05, P=.496), with a significant interaction (Pinteraction=.036). CONCLUSIONS: In contrast to the known survival benefit when ADT is given with EBRT, our results suggest that ADT might not improve survival for high-risk patients who undergo combined EBRT and brachytherapy. Given the significant adverse effects of ADT, in particular, with long-term therapy, a randomized controlled trial of combined EBRT and brachytherapy with or without ADT for select high-risk patients using a noninferiority design should be undertaken.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yang DD, Muralidhar V, Mahal BA, et al. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29254781. doi:10.1016/j.ijrobp.2017.08.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。